Scientists Present New ‘Roadmap’ for Addressing Future Coronavirus Threats–Some Experts Fault the Directions

In February the University of Minnesota’s Center for Infectious Disease Research and Policy, (CIDRAP), released their annual report. Coronavirus Vaccines R&D Roadmap. This controversial document was compiled and funded by Rockefeller Foundation and Bill and Melinda Gates Foundation (BMFG) by more than 50 scientists.

“The COVID-19 pandemic marks the third time in just 20 years that a coronavirus has emerged to cause a public health crisis,” Director of CIDRAP Prof. Michael Osterholm said Press release

“Rather than waiting for a fourth coronavirus to emerge—or for the arrival of an especially dangerous SARS-CoV-2 variant—we must act now to develop better, longer-lasting, and more broadly protective vaccines,” Osterholm has been added

The Roadmap admits the shortcomings of current COVID vaccines, boosters in a surprisingly honest manner:

“The limited durability and immunologic protection of currently available SARS-CoV-2 vaccines further highlight the crucial need for a new, proactive approach to develop coronavirus vaccines that provide better and longer protection against both circulating and future SARS-CoV-2 variants and other coronaviruses that have not yet emerged.”

These authors note that other SARS-CoV-2 strains than COVID can be deadly. For example, the Middle East Respiratory Syndrome Coronavirus was found in 2012 and had a 35% case fatality rate.

You can compare this rate to COVID-19. mortality rate Of 1.08 percent though data from the Centers for Disease Control and Prevention Covering the quarter ending in 2022, a death rate of less than 22 for every 100,000 people or 0.022 percent was recorded.

David Bell is a senior researcher at Brownstone Institute and a physician in public health who used to work for the World Health Organization. He told The Epoch Times by email that the Roadmap seems exaggerated about the coronavirus threat.

“Essentially, they are massively inflating a historically minor health issue (two coronavirus outbreaks since 2020—far more people die every year from heart disease in the U.S., or from cancer, and at a younger age, than the highest annual COVID mortality, which is likely two to three times the true rate). Mortality [for these viruses] was historically minimal, about 1/500 of normal annual flu mortality.”

Considering the SARS-CoV-2 threat, the Coronavirus Vaccines R&D Roadmap proposes five areas for intensive research:

• Virology: It is important to emphasize the importance of further research “collect, characterize, and share viral information from the full range of wild and captive animal reservoirs worldwide.”
• Immunology: It is important to focus on increasing the effectiveness and longevity of natural and vaccine-induced immunity.
• Vaccinology: Develop new technologies for vaccines “expand breadth of coverage, durability of protection, and feasibility of use worldwide, including in low-resource [developing world] settings.”
• Infection models for animals and humans: Develop more precise models to test vaccine results in animal and human clinical trials.
• Policies and financing: It is argued that the successful development of broad-protective coronavirus vaccines and their widespread availability will depend on sustaining high levels of political commitment to vaccine research, surveillance and global production and distribution.

Fauci’s Admission Of Vaccine Deficits

A number of people have echoed the sentiments expressed in regards to the relative efficacy of current vaccines. paper published in January—with surprisingly little mainstream media coverage—in Cell Host and Microbe. Anthony Fauci was one of the authors.

“Attempting to control mucosal respiratory viruses with systemically administered non-replicating vaccines has thus far been largely unsuccessful, indicating that new approaches are needed.”

This paper was co-authored with the retired director of National Institute for Allergies and Infectious Diseases.